Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;8(3):271-278.
doi: 10.1016/j.jare.2017.02.003. Epub 2017 Feb 27.

Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review

Usama A Sharaf El Din  1 , Mona M Salem  2 , Dina O Abdulazim  3
Affiliations
Review

Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review

Usama A Sharaf El Din et al. J Adv Res. 2017 May.

Abstract

The death rate among chronic kidney disease patients is the highest compared to other chronic diseases. 60% of these fatalities are cardiovascular. Cardiovascular calcifications and chronic inflammation affect almost all chronic kidney disease patients and are associated with cardiovascular mortality. Fibroblast growth factor 23 is associated with vascular calcification. Systemic inflammation in chronic kidney disease patients is multifactorial. The role of systemic inflammation in the pathogenesis of vascular calcification was recently reappraised. Fibroblast growth factor 23 was accused as a direct stimulus of left ventricular hypertrophy, uremic inflammation, and impaired neutrophil function. This review will discuss the underlying mechanisms that underlie the link between Fibroblast growth factor 23 and increased mortality encountered among chronic kidney disease patients.

Keywords: Chronic kidney disease; Fibroblast growth factor 23; Inflammation; Left ventricular hypertrophy; Mortality; Vascular calcification.

PubMed Disclaimer

Figures

None
Graphical abstract
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2(3): REVIEWS3005, 2001. - PMC - PubMed
    1. Liu S., Quarles L.D. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18:1637–1647. - PubMed
    1. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215. - PubMed
    1. Viaene L., Bammens B., Meijers B.K., Vanrenterghem Y., Vanderschueren D., Evenepoel P. Residual renal function is an independent determinant of serum fgf-23 levels in dialysis patients. Nephrol Dial Transplant. 2012;27:2017–2022. - PubMed
    1. Nasrallah M.M., El-Shehaby A.R., Salem M.M., Osman N.A., El Sheikh E., Sharaf El Din U.A. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:2679–2685. - PubMed

LinkOut - more resources